Silo Pharma, Medspray make deal for nasal spray delivery of PTSD, anxiety drug

A new licensing agreement between Silo Pharma and Medspray Pharma BV allows SPC-15, Silo’s therapeutic for PTSD, anxiety and more, to be delivered via Medspray’s soft mist nasal spray technology, according to a Silo press release.

“As part of our manufacturing and sales contract, we have obtained exclusive rights to [Medspray’s] spray mist technology for use with multiple indications including PTSD and anxiety, as well as Alzheimer’s disease and anorexia,” Eric Weisblum, Silo’s CEO, said in the release. “We believe these rights are a valuable asset that can support Silo’s continuing research and development of novel therapeutics.”

SPC-15 is a novel serotonin 4 inhibitor being developed as an intranasal treatment for stress-induced affective disorders, according to the release. Medspray’s technology uses silicon microchip-based nozzles to emit an aerosol plume designed to deposit the formulation in the relevant part of the nasal cavity.

Silo selected Medspray to provide SPC-15’s delivery mechanism following successful results of feasibility studies the companies conducted over the course of this year, Weisblum said in the release.

SPC-15 is currently in preclinical studies in collaboration with Columbia University. The drug could qualify for the FDA’s streamlined 505(b)(2) approval pathway if clinically successful, according to Silo.